Dermira jumps on Phase IIb atopic dermatitis readout

Dermira added $5.77 (84%) to $12.61 on Monday after reporting that all three doses of lebrikizumab met the primary endpoint in a

Read the full 227 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE